Mpviropack Plus: Real Life Study

Mohamed Baddar⁴, Taher el Zanaty², Reda Amer², Mohsen Salama⁵, Ramy M Elsharkawy⁶, Hazem Elbedawei⁷ , Alaa Osman Elroby⁸, Osama A Sabry⁹, Tamer G¹⁰ , Hares M¹¹ , Ayman El Badawy¹³, Nader A Nemr¹², Mohamed M Aamer¹⁴, Nashaat Hawass¹², George Marzouk¹⁵, Sherif Ragheb¹⁵, Mohamed B Hashem*¹ and Esmat G¹

Received: March 12, 2018;   Published: April 05, 2018

DOI: 10.26717/BJSTR.2018.03.000918

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF

Abstract

Egypt has the highest prevalence of HCV worldwide. It is estimated to be 7.3% which is considered more than double the global prevalence that is estimated to be 3% according to the World Health Organization (WHO). The main genotype in Egypt is genotype 4 [1]. For many years ago, HCV treatment remained a challenge, where the available regimens were the moderately potent but poorly tolerated combination of pegylated interferon (PegIFN) and ribavirin for 24 or 48 weeks [2]. Using this combination, HCV genotype 4 patients had intermediate SVR rates (50-60%) [3]. Since 2011, multiple new drugs acting on specific enzymatic sites throughout the HCV life cycle were developed (direct acting antiviral drugs DAAs). DAAs are more potent than the INF/RBV with bettersafety profile. DAAs are now widely available worldwide [4].

Abbreviations: WHO: World Health Organization; PegIFN: Pegylated Interferon; DAAs: Direct Acting Antiviral Drugs Daas; AST: Aspartate Transaminase; ALT: Alanine Transaminase; ALB: Albumin; INR: International Normalized Ratio; CBC: Complete Blood Count; AFP: Alpha Feto Protein; FBS: Fasting Blood Sugar; SVR: Sustained Virological Response

Introduction| Patients and Methods| Results| Discussion| Conclusion| References|